The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy

Recruiting now

Conditions studied: Breast Neoplasms

In brief

This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.

Key facts

Study ID
NCT06318507
Run by
Pennington Biomedical Research Center
People needed
25
Starts
2024-03-11
Expected to finish
2026-12-31
Last updated by the study team
2025-02-17

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.